The Lancet Global Health Estimating the cost of vaccine development against epidemic infectious diseases: a cost minimisation study Dimitrios Gouglas, MSc, Tung Thanh Le, MSc, Klara Henderson, PhD, Prof Aristidis Kaloudis, PhD, Trygve Danielsen, MSc, Nicholas Caspersen Hammersland, MSc, James M Robinson, MS, Penny M Heaton, MD, Prof John-Arne Røttingen, MD The Lancet Global Health DOI: 10.1016/S2214-109X(18)30346-2 Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND 4.0 license Terms and Conditions
Figure Estimated cost of progressing at least one epidemic infectious disease vaccine from preclinical through to end of phase 2a PoS=probabilities of success. Figures in US$. The Lancet Global Health DOI: (10.1016/S2214-109X(18)30346-2) Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND 4.0 license Terms and Conditions